The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.

Among the many types of denials from insurance companies that come across my desk, one I have been seeing more frequently is the "DRG...

João Bocas - The Wearables Expert ™ interviews Charles Michael Gibson, MD. CEO of Baim Institute for Clinical Research, (FKA Harvard Clinical Research Institute...

Large health insurance companies are dominating the Medicare Advantage (MA) market and gaming the system to maximize profits. The loser in the push to privatize Medicare is seniors